Evolving Therapies For Multiple Sclerosis

International Review of Neurobiology

Volumn 79, Issue , 2007, Pages 571-588

  Korniychuk, Elena ^a   Dempster, John M ^a   O'Connor, Eileen ^b   Alexander, J Steven ^c   Kelley, Roger E ^a   Kenner, Meghan ^a   Menon, Uma ^a   Misra, Vivek ^a   Hoque, Romy ^a   Gonzalez Toledo, Eduardo ^c   Schwendimann, Robert N ^a   Smith, Stacy ^a   Minagar, Alireza ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b BIOGEN   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; VITAMIN D;

ANIMAL; HUMAN; METHODOLOGY; MULTIPLE SCLEROSIS; REVIEW; STEM CELL TRANSPLANTATION; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; STEM CELL TRANSPLANTATION; VACCINATION; VITAMIN D;

EID: 34248642554     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(07)79025-6     Document Type: Review

References (74)

1. Anderson K.C., Bates M.P., Slaughenhoupt B.L., Pinkus G.S., Schlossman S.F., and Nadler L.M. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63 (1984) 1424-1433
2. Back S.A., Tuohy T.M., Chen H., Wallingford N., Craig A., Struve J., Luo N.L., Banine F., Liu Y., Chang A., Trapp B.D., Bebo Jr. B.F., et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 11 (2005) 966-972
3. Birnbaum G., and Altafullah I. A double blind, placebo controlled combination trial of interferon beta1a (Rebif) and atorvastatin (Lipitor) in patients with relapsing remitting multiple sclerosis [abstract# P06.158]. Proceedings of the 57th Meeting of the American Academy of Neurology: 2005 April 9-16; Miami Beach (2005), American Academy of Neurology Press, St Paul
4. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C.A., Zollinger M., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277 (2002) 21453-21457
5. Brinkmann V., Cyster J.G., and Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4 (2004) 1019-1025
6. Brundula V., Rewcastle N.B., Metz L.M., Bernard C.C., and Yong V.W. Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis. Brain 125 (2002) 1297-1308
7. Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M., Lucas D., and Reed J.C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
8. 3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 93 (1996) 7861-7864
9. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6 (2000) 797-801
10. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6 (2000) 443-446
11. Coles A., Deans J., and Compston A. Campath-1H treatment of multiple sclerosis: Lessons from the bedside for the bench. Clin. Neurol. Neurosurg. 106 (2004) 270-274
12. Coles A.J., Wing M.G., Molyneux P., Paolillo A., Davie C.M., Hale G., Miller D., Waldmann H., and Compston A. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46 (1999) 296-304
13. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., and Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 (2005) 1270-1272
14. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 98 (2001) 14669-14674
15. Einfeld D.A., Brown J.P., Valentine M.A., Clark E.A., and Ledbetter J.A. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7 (1988) 711-717
16. Fan L.W., Pang Y., Lin S., Rhodes P.G., and Cai Z. Minocycline attenuates liposaccharide-induced white matter injury in neonatal rat brain. Neuroscience 133 (2005) 159-168
17. Flieger D., Renoth S., Beier I., Sauerbruch T., and Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 204 (2000) 55-63
18. Frohman E.M., Racke M.K., and Raine C.S. Multiple sclerosis: The plaque and its pathogenesis. N. Engl. J. Med. 354 (2005) 942-955
19. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., Vyhnalek P., Zadorova Z., Palmer T., Donoghue S.,, and and Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348 (2003) 24-32
20. Giuliani F., Hader W., and Yong V.W. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J. Leukocyte Biol. 78 (2005) 135-143
21. Giuliani F., Metz L.M., Wilson T., Fan Y., Bar-Or A., and Yong V.W. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158 (2005) 213-221
22. Giuliani F., Fu S.A., Metz L.M., and Yong V.W. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J. Neuroimmunol. 165 (2005) 83-91
23. Hayes C.E., Nashold F.E., Spach K.M., and Pedersen L.B. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-grand) 49 (2003) 277-300
24. Hernan M.A., Olek M.J., and Ascherio A. Geographic variation of MS incidence in two prospective studies of US woman. Neurology 531 (1999) 1711-1718
25. Hong J., Zang Y.C., Nie H., and Zhang J.Z. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 103 (2006) 5024-5029
26. Hunter C.L., Bachman D., and Granholm A.C. Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann. Neurol. 56 (2004) 675-688
27. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., and Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 358 (2001) 1500-1503
28. Ifergan I., Wosik K., Cayrol R., Kebir H., Auger C., Bernard M., Bouthillier A., Moumdjian R., Duquette P., and Prat A. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis. Ann. Neurol. 60 (2006) 45-55
29. Jackson D.Y. Alpha 4 integrin antagonists. Curr. Pharm. Des. 8 (2002) 1229-1253
30. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., Haas T., Korn A.A., Karlsson G., Radue E.W., and FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355 (2006) 1124-1140
31. Kriz J., Nguyen M.D., and Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10 (2002) 268-278
32. Lemire J.M. Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J. Steroid. Biochem. Mol. Biol. 53 (1995) 599-602
33. Li S., Xu J., Makarenkova V.P., Tjandrawan T., Vakkila J., Reichert T., Gooding W., Lagenaur C.F., Achim C.L., Chambers W.H., Herberman R.B., Whiteside T.L., et al. A novel epitope of N-CAM defines precursors of human adherent NK cells. J. Leukoc. Biol. 76 (2003) 1187-1199
34. Mach F. Toward a role for statins in immunomodulation. Mol. Interv. 2 (2002) 478-480
35. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., Janakiraman N., Foon K.A., Liles T.M., Dallaire B.K., Wey K., Royston I., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 2188-2195
36. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
37. Mark B.L., and Carson J.A. Vitamin D and autoimmune disease-implications for practice from the multiple sclerosis literature. J. Am. Dietetic. Assoc. 106 (2006) 418-424
38. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W.,, and and International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348 (2003) 15-23
39. Minagar A., Alexander J.S., Brooks R., Kelley R.E., Schwendimann R.N., Gonzalez-Toledo E., and Merill-Bryanm D. Combination therapy with intramuscular interferon-beta1a and oral doxycycline in patients with multiple slerosis: An open label trial. Neurology A34 Suppl. 2 (2005) P01.087
40. Moreau T., Thorpe J., Miller D., Moseley I., Hale G., Waldmann H., Clayton D., Wing M., Scolding N., and Compston A. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344 (1994) 298-301
41. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., and Archelos J.J. Statins as immunomodulators: Comparsion with interferon-beta 1b in MS. Neurology 59 (2000) 990-997
42. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
43. Paolillo A., Coles A.J., Molyneux P.D., Gawne-Cain M., MacManus D., Barker G.J., Compston D.A., and Miller D.H. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53 (1999) 751-757
44. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., and Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99 (2002) 1314-1319
45. Pinschewer D.D., Ochsenbein A.F., Odermatt B., Brinkmann V., Hengartner H., and Zinkernagel R.M. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164 (2000) 5761-5770
46. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 899-910
47. Popovic N., Schubart A., Goetz B.D., Zhang S.C., Linington C., and Duncan I.D. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 51 (2002) 215-223
48. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., and Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
49. Rose J.W., Watt H.E., White A.T., and Carlson N.G. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 56 (2004) 864-867
50. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., Lublin F.D., Weinstock-Guttman B., Wynn D.L., Lynn F., Panzara M.A., Sandrock A.W., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 911-923
51. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: A review. Clin. Transplant. 19 (2005) 705-710
52. Sasaki M., Bharwani S., Jordan P., Joh T., Manas K., Warren A., Harada H., Carter P., Elrod J.W., Wolcott M., Grisham M.B., and Alexander J.S. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J. Pharmacol. Exp. Ther. 305 (2003) 78-85
53. Shan D., Ledbetter J.A., and Press O.W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48 (2000) 673-683
54. Sheremata W.A., Minagar A., Alexander J.S., and Vollmer T. The role of alpha-4 integrin in the aetiology of multiple sclerosis: Current knowledge and therapeutic implications. CNS Drugs 19 (2005) 909-922
55. Soilu-Hanninen M., Airas L., Mononen I., Heikkila A., Vijanen M., and Hanninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 11 (2005) 266-271
56. Spach K.M., Nashold F.E., Dittel B.N., and Hayes C.E. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol. 177 (2006) 6030-6037
57. Stirling D.P., Khodarahmi K.J., Liu L., McPhail T., McBride C.B., Steeves J.D., Ramer M.S., and Tetzlaff W. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. 24 (2004) 2182-2190
58. Stuve O., Cepok S., Elias B., Saleh A., Hartung H.P., Hemmer B., and Kieseier B.C. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. 62 (2005) 1620-1623
59. Taji H., Kagami Y., Okada Y., Andou M., Nishi Y., Saito H., Seto M., and Morishima Y. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn. J. Cancer Res. 89 (1998) 748-756
60. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
61. Tokuda N., and Levy R.B. 1,25-Dihydroxyvitamin D3 stimulates phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. Proc. Soc. Exp. Biol. Med. 211 (1996) 244-250
62. Valentine M.A., Meier K.E., Rossie S., and Clark E.A. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase. C. J. Biol. Chem. 264 (1989) 11282-11287
63. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., Preiningerova J., Rizzo M., and Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
64. Weber M.S., Youssef S., Dunn S.E., Prod'homme T., Neuhaus O., Stuve O., Greenwood J., Steinman L., and Zamvil S.S. Statins in the treatment of central nervous system autoimmune disease. J. Neuroimmunol. 178 (2006) 140-148
65. Wells J.E., Hurlbert R.J., Fehlings M.G., and Yong V.W. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 126 (2003) 1628-1637
66. Windrem M.S., Nunes M.C., Rashbaum W.K., Schwartz T.H., Goodman R.A., McKhann II G., Roy N.S., and Goldman S.A. Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nat. Med. 10 (2004) 93-97
67. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
68. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., and Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356 (1992) 63-66
69. Yong V.W. Prospects for neuroprotection in multiple sclerosis. J. Neuroimmunol. 9 (2004) 864-872
70. Yong V.W., Wellsm J., Giuliani F., Casha S., Power C., and Metz L.M. The promise of minocycline in neurology. Lancet Neurol. 3 (2004) 744-751
71. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
72. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., and Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. USA 95 (1998) 15769-15774
73. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA 96 (1999) 13496-13500
74. Zella J.B., McCary L.C., and DeLuca H.F. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch. Biochem. Biophys. 417 (2003) 77-80